icon-folder.gif   Conference Reports for NATAP  
 
  HIV Glasgow 2020, 5-8 October
Virtual Meeting
Back grey_arrow_rt.gif
 
 
 
COMPARABILITY OF 48-WEEK EFFICACY AND SAFETY OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING EVERY 8 WEEKS TO STANDARD OF CARE IN SUPPRESSED PEOPLE LIVING WITH HIV-1
 
 
  Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
 
Vasiliki Chounta,1 Sonya Snedecor,2 Sterling Wu,3 Nicolas Van de Velde1 1ViiV Healthcare, Brentford, UK; 2Pharmerit International, Bethesda, MD, USA; 3GlaxoSmithKline, Collegeville, PA, USA

1005201

1005202

1005203

1005204